Samuel Keith

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi request reprint Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics
    Samuel J Keith
    J Clin Psychiatry 65:120-31. 2004
  2. ncbi request reprint Advances in psychotropic formulations
    Samuel Keith
    Department of Psychiatry and Psychology, University of New Mexico, 2400 Tucker, NE Room 404, Albuquerque, 87131, USA
    Prog Neuropsychopharmacol Biol Psychiatry 30:996-1008. 2006
  3. doi request reprint Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness
    Samuel Keith
    Department of Psychiatry, 2400 Tucker, NE Room 404, Albuquerque, NM 87131, USA
    Expert Rev Neurother 9:9-31. 2009
  4. ncbi request reprint Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia
    Samuel J Keith
    Department of Psychiatry, University of New Mexico, Albuquerque 87131 1161, USA
    Psychiatr Serv 55:997-1005. 2004
  5. ncbi request reprint Partial compliance and patient consequences in schizophrenia: our patients can do better
    Samuel J Keith
    Department of Psychiatry, University of New Mexico, Albuquerque 87131 1161, USA
    J Clin Psychiatry 64:1308-15. 2003
  6. ncbi request reprint Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients
    Juan R Bustillo
    Department of Psychiatry, Research Division, 2400 Tucker NE, University of New Mexico, Albuquerque, NM 87131, USA
    Neuropsychopharmacology 28:527-9. 2003
  7. ncbi request reprint Integrated treatment of schizophrenia
    Roshel Lenroot
    Department of Psychiatry, School of Medicine, University of New Mexico, 2400 Tucker NE, Albuquerque, NM 87131, USA
    Psychiatr Serv 54:1499-507. 2003
  8. ncbi request reprint Are we still talking to our patients with schizophrenia?
    Samuel J Keith
    Am J Psychiatry 163:362-4. 2006
  9. ncbi request reprint Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
  10. ncbi request reprint Ten days matter
    Samuel J Keith
    Psychiatr Serv 55:857. 2004

Detail Information

Publications10

  1. ncbi request reprint Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics
    Samuel J Keith
    J Clin Psychiatry 65:120-31. 2004
  2. ncbi request reprint Advances in psychotropic formulations
    Samuel Keith
    Department of Psychiatry and Psychology, University of New Mexico, 2400 Tucker, NE Room 404, Albuquerque, 87131, USA
    Prog Neuropsychopharmacol Biol Psychiatry 30:996-1008. 2006
    ..A number of innovative delivery systems have been developed to address suboptimal therapy outcomes by enhancing drug delivery, assuring efficacy of treatment, reducing side effects, and improving compliance...
  3. doi request reprint Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness
    Samuel Keith
    Department of Psychiatry, 2400 Tucker, NE Room 404, Albuquerque, NM 87131, USA
    Expert Rev Neurother 9:9-31. 2009
    ....
  4. ncbi request reprint Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia
    Samuel J Keith
    Department of Psychiatry, University of New Mexico, Albuquerque 87131 1161, USA
    Psychiatr Serv 55:997-1005. 2004
    ..This article provides practical advice to physicians on the characteristics of patients who would benefit from treatment with long-acting atypical antipsychotic agents and offers suggestions on how to initiate treatment...
  5. ncbi request reprint Partial compliance and patient consequences in schizophrenia: our patients can do better
    Samuel J Keith
    Department of Psychiatry, University of New Mexico, Albuquerque 87131 1161, USA
    J Clin Psychiatry 64:1308-15. 2003
    ..The primary objective of this review is to evaluate the strategies used to improve patient compliance with antipsychotic medication in the treatment of schizophrenia...
  6. ncbi request reprint Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients
    Juan R Bustillo
    Department of Psychiatry, Research Division, 2400 Tucker NE, University of New Mexico, Albuquerque, NM 87131, USA
    Neuropsychopharmacology 28:527-9. 2003
    ..Serotonin reuptake inhibitors are probably not a practical option to counteract weight gain induced by atypical antipsychotics. Atypical-induced weight gain may result from mechanisms other than 5HT reuptake blockade...
  7. ncbi request reprint Integrated treatment of schizophrenia
    Roshel Lenroot
    Department of Psychiatry, School of Medicine, University of New Mexico, 2400 Tucker NE, Albuquerque, NM 87131, USA
    Psychiatr Serv 54:1499-507. 2003
    ..Emphasis is placed on areas of interaction, including patient adherence and the effect of antipsychotic medications on cognitive functioning. Recommendations are presented for specific clinical situations...
  8. ncbi request reprint Are we still talking to our patients with schizophrenia?
    Samuel J Keith
    Am J Psychiatry 163:362-4. 2006
  9. ncbi request reprint Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia...
  10. ncbi request reprint Ten days matter
    Samuel J Keith
    Psychiatr Serv 55:857. 2004